StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30126% above fair value
$21.89−0.22 (-1.00%)

Close on Nov 18, 2026Market cap $3.69BP/E –Yield –

Tango Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Tango Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $53.81M, up 121.5% year over year. For fiscal 2025 it was $62.38M, up 48.3% from the year before. The highest annual figure on record is $62.38M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$62.38M+48.3%
FY2024Dec 31, 2024$42.07M+15.2%
FY2023Dec 31, 2023$36.53M+46.9%
FY2022Dec 31, 2022$24.86M-32.9%
FY2021Dec 31, 2021$37.04M+383.8%
FY2020Dec 31, 2020$7.66M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$53.81M+363.6%
Q2 FY2025Jun 30, 2025$3.18M-84.0%
Q1 FY2025Mar 31, 2025$5.39M-16.7%
Q4 FY2024Dec 31, 2024$4.12M-24.2%
Q3 FY2024Sep 30, 2024$11.61M+8.2%
Q2 FY2024Jun 30, 2024$19.88M+36.1%
Q1 FY2024Mar 31, 2024$6.47M+12.2%
Q4 FY2023Dec 31, 2023$5.43M-15.3%
Q3 FY2023Sep 30, 2023$10.73M+55.1%
Q2 FY2023Jun 30, 2023$14.60M+153.0%
Q1 FY2023Mar 31, 2023$5.77M+0.1%
Q4 FY2022Dec 31, 2022$6.41M+12.2%
Q3 FY2022Sep 30, 2022$6.92M+2.0%
Q2 FY2022Jun 30, 2022$5.77M-68.2%
Q1 FY2022Mar 31, 2022$5.76M-9.8%
Q4 FY2021Dec 31, 2021$5.72M-37.5%
Q3 FY2021Sep 30, 2021$6.79M–
Q2 FY2021Jun 30, 2021$18.15M–
Q1 FY2021Mar 31, 2021$6.39M–
Q4 FY2020Dec 31, 2020$9.14M–
Q3 FY2020Sep 30, 2020-$11.26M–

More Tango Therapeutics figures

See a number that looks wrong?